Breaking News Instant updates and real-time market news.

Q

symbol changed to IQV

$87.55

-0.32 (-0.36%)

, MRK

Merck

09:45
06/20/17
06/20
09:45
06/20/17
09:45

Barclays biopharmaceuticals analysts hold an analyst/industry conference call

Biopharmaceuticals Research Team provide an update on the immuno-oncology demand trends, with Merck's Keytruda the most commonly used agent, slightly ahead of Lilly's Alimta in PD-L1, along with Bristol's Opdivo and Roche's Tecentriq in 2L, on an Analyst/Industry conference call to be held on June 20 at 10 am.

Q

symbol changed to IQV

$87.55

-0.32 (-0.36%)

MRK

Merck

LLY

Eli Lilly

BMY

Bristol-Myers

$55.26

0.04 (0.07%)

RHHBY

Roche

$32.88

0.07 (0.21%)

  • 20

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jul

  • 22

    Sep

  • 24

    Sep

Q symbol changed to IQV
$87.55

-0.32 (-0.36%)

06/12/17
KEYB
06/12/17
NO CHANGE
KEYB
CROs should benefit from growth of risk-based monitoring, says KeyBanc
KeyBanc says that industry guidelines recently adopted by the EU should be a catalyst for risk-based monitoring technologies, or RBM. KeyBanc says that CROs such as QuintilesIMS (Q) and ICON plc (ICON) can bundle their risk-based monitoring software-as-a-service with their other services, generating efficiencies which can increase their profits. The analyst adds that the increased use of RBM should increase the CROs' gross margins and market share over the longer run. The firm raised its price target on QuintilesIMS to $96 from $90 and on ICON to $103 from $98. It keeps Overweight ratings on QuintilesIMS and ICON.
02/17/17
WELS
02/17/17
UPGRADE
WELS
Outperform
QuintilesIMS upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans upgraded QuintilesIMS to Outperform following a review of the company's annual filing. A "controversial and complex merger story now looks less risky," Evans tells investors in a research note. The analyst forecasts annual earnings growth of 15%-20% for the 2018-2020 period. He has a $90-$92 price target range for QuintilesIMS shares.
05/03/17
WELS
05/03/17
DOWNGRADE
WELS
Market Perform
Medpace downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Tim Evans downgraded Medpace (MEDP) to Market Perform saying the company has "considerably lower visibility than peers" on 2017 and 2018. The analyst prefers contract research organizations that are most likely to be share takers in an increasingly competitive environment. He lowered his price target range for the shares to $23-$25 from $32-$33. Evans this morning also downgraded INC Research (INCR) to Market Perform. He views PRA Health (PRAH), ICON plc (ICLR) and QuintilesIMS (Q) as share takers in the CRO space.
03/31/17
FBCO
03/31/17
INITIATION
Target $89
FBCO
Outperform
QuintilesIMS initiated with an Outperform at Credit Suisse
Credit Suisse analyst Erin Wilson Wright started QuintilesIMS with an Outperform rating and an $89 price target saying it should benefit from sustained strength in outsourcing demand while leveraging its leading global healthcare information and technology platform.
MRK Merck

06/13/17
FBCO
06/13/17
NO CHANGE
FBCO
Outperform
Merck Keytruda trials pause doesn't seem like major concern, says Credit Suisse
After speaking with Merck, Credit Suisse analyst Vamil Divan said the company confirmed that its pause of two trials of Keytruda in multiple myeloma is not a clinical hold. While it is still difficult to draw meaningful conclusions, Divan doesn't believe this is a major concern given Keytruda's clean safety profile to date. The analyst, who adds that he doesn't see any material impact on Merck's near-term prospects in immuno-oncology from this pause, keeps an Outperform rating on the stock.
06/06/17
BMOC
06/06/17
NO CHANGE
BMOC
Incyte should be bought on recent weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that data on the combination of Bristol-Myers' (BMY) Opdivo and Incyte's (INCY) epacadostat "confirmed the benefit" seen in a previous study. The analyst says that the safety of Merck's (MRK) Keytruda in combination with epacadostat is better than the standard of care. He keeps a $166 price target and Outperform rating on Incyte.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/05/17
PIPR
06/05/17
NO CHANGE
PIPR
Piper views AstraZeneca, J&J as ASCO standouts
The standouts at ASCO over the weekend were the "compelling results" presented on Johnson & Johnson's (JNJ) Zytiga from the Latitude study in prostate cancer and AstraZeneca's (AZN) Lynparza in the OlympiAD trial in BRCA mutant breast cancer, Piper Jaffray analyst Richard Purkiss tells investors in a research note. In lung cancer, Merck's (MRK) updated data in KN021G "appears more promising" than Bristol-Myers' (BMY) updated data in CM012, the analyst adds. Purkiss believes, however, that relative to recent ASCOs, the data "so far in totality is underwhelming."
LLY Eli Lilly

06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
06/12/17
LEER
06/12/17
NO CHANGE
Target $90
LEER
Outperform
Eli Lilly price target lowered to $90 from $93 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Eli Lilly (LLY) to $90 to reflect reduced sales forecasts for baricitinib, an oral JAK1/2 inhibitor to treat rheumatoid arthritis which the company collaborates with Incyte (INCY). Following AbbVie's (ABBV) positive Phase 3 data last week for its JAK1 inhibitor upadacitinib, Fernandez dropped his U.S. peak sales estimate for baricitinib by more than 50% to $400M and pushed out his U.S. launch time to 2020 from 2018. The analyst keeps an Outperform rating on Lilly shares.
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.
BMY Bristol-Myers
$55.26

0.04 (0.07%)

06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Credit Suisse sees no impact to Incyte's epacadostat from NewLink IDO news
Credit Suisse analyst Alethia Young said she is not surprised that Roche (RHHBY) returned IDO inhibitor GDC-0919 to NewLink (NLNK) after seeing the "disappointing data" at ASCO. She doesn't see an impact to Incyte's (INCY) own IDO inhibitor, epacadostat, from the news, as she thought the data made GDC-0919 appear clinically inferior to epacadostat in combination with PD-1. She keeps an Outperform rating on Incyte shares, adding that investors may get another update on Bristol-Myers' (BMY) internal IDO, BMS-986205, later this year.
06/06/17
RHCO
06/06/17
NO CHANGE
RHCO
Bristol-Myers data 'encouraging,' says SunTrust
SunTrust analyst John Boris says that the data on a combination utilizing Bristol-Myers' Opdivo in colorectal cancer was "encouraging," although only a small number of patients participated in the trial. He says that FDA action involving Opdivo's use as a treatment for colorectal cancer and hepatic cancer can be catalysts for the stock. However, he keeps a Hold rating on Bristol-Myers.
RHHBY Roche
$32.88

0.07 (0.21%)

06/08/17
RHCO
06/08/17
NO CHANGE
RHCO
Buy
SunTrust says GDC-0919 represents only 20% of NewLink target
After Roche (RHHBY) decided to return the rights of GDC-0919, SunTrust analyst Peter Lawson says the drug represents 20%, or $6, of his $30 price target for NewLink Genetics (NLNK). The analyst does not believe today's news has any read through for indoximod. He as a Buy rating on NewLink.
06/08/17
CANT
06/08/17
NO CHANGE
Target $32
CANT
Overweight
NewLink, Roche research collaboration remains intact, says Cantor
Cantor Fitzgerald analyst Mara Goldstein says that while Roche's (RHHBY) decision to return the rights to GDC-091 is disappointing, the broader research collaboration with NewLink Genetics (NLNK) on next-generation IDO compounds remains intact. The analyst notes that her $32 price target for NewLink is under review. Goldstein expects further clarity around the future of GDC-091 as NewLink begins evaluation later this year. The analyst has an Overweight rating on the shares.
06/08/17
STFL
06/08/17
NO CHANGE
STFL
Buy
Stifel would not be selling NewLink into navoximod handback weakness
Stifel analyst Stephen Willey said he views Roche's (RHHBY) decision to return the rights for navoximod to NewLink Genetics (NLNK) as both "surprising" and "disappointing" and noted that the extent to which the decision was driven by asset versus mechanism of action versus competitive concerns is still unknown. However, wouldn't be selling NewLink shares into the early weakness as he still believes indoximod to be "an asset of value/interest." Willey has a Buy rating on NewLink shares.

TODAY'S FREE FLY STORIES

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$279.60

0.46 (0.16%)

12:36
01/19/18
01/19
12:36
01/19/18
12:36
Periodicals
Trump seeks meeting with Schumer to avert shutdown, NY Times reports »

Maggie Haberman of the…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$279.60

0.46 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:31
01/19/18
01/19
12:31
01/19/18
12:31
Hot Stocks
Breaking Hot Stocks news story on NuCana »

NuCana resumes, up 43% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.49

0.35 (0.13%)

, IEMG

iShares Core MSCI Emerging Markets

$60.61

0.305 (0.51%)

12:30
01/19/18
01/19
12:30
01/19/18
12:30
Technical Analysis
On The Fly: ETF fund flow highlights »

Flows continued to be…

SPY

SPDR S&P 500 ETF Trust

$279.49

0.35 (0.13%)

IEMG

iShares Core MSCI Emerging Markets

$60.61

0.305 (0.51%)

IEFA

iShares Core MSCI EAFE ETF

$69.52

0.215 (0.31%)

EWJ

iShares MSCI Japan Index Fund

$63.74

0.31 (0.49%)

BNDX

Vanguard Total International Bond ETF

$54.18

-0.02 (-0.04%)

EEM

MSCI Emerging Markets Index

$50.31

0.2775 (0.55%)

IWM

iShares Trust Russell 2000 Index Fund

$157.91

1.37 (0.88%)

GLD

SPDR Gold Trust

$126.65

0.79 (0.63%)

SVXY

ProShares Short VIX Short-Term Futures

$131.85

-0.45 (-0.34%)

IWD

iShares Russell 1000 Value

$128.57

0.09 (0.07%)

JNK

SPDR Barclays High Yield Bond

$36.80

-0.015 (-0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$119.83

-0.315 (-0.26%)

IEF

iShares 7-10 Year Treasury Bond ETF

$104.06

-0.33 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:30
01/19/18
01/19
12:30
01/19/18
12:30
Hot Stocks
Breaking Hot Stocks news story on NuCana »

NuCana PLC (ADS) trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$162.44

-6.68 (-3.95%)

, AXP

American Express

$97.11

-2.75 (-2.75%)

12:29
01/19/18
01/19
12:29
01/19/18
12:29
General news
On The Fly: Top stock stories at midday »

Stocks opened with minor…

IBM

IBM

$162.44

-6.68 (-3.95%)

AXP

American Express

$97.11

-2.75 (-2.75%)

GE

General Electric

$16.35

-0.425 (-2.53%)

ACOR

Acorda Therapeutics

$25.00

0.25 (1.01%)

BIIB

Biogen

$344.44

-0.43 (-0.12%)

NKE

Nike

$66.64

2.525 (3.94%)

IPHI

Inphi

$33.39

-2.01 (-5.68%)

MKC

McCormick

$98.72

-4.19 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 07

    Feb

  • 08

    Mar

EA

Electronic Arts

$115.28

2.14 (1.89%)

, ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

12:28
01/19/18
01/19
12:28
01/19/18
12:28
Hot Stocks
EA in focus after NPD says 'Battlefront II' second-best selling game in December »

Shares of Electronic Arts…

EA

Electronic Arts

$115.28

2.14 (1.89%)

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

TTWO

Take-Two

$117.27

1.18 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 08

    Feb

  • 21

    Feb

  • 22

    Feb

  • 07

    Dec

12:25
01/19/18
01/19
12:25
01/19/18
12:25
General news
Treasury's $25 M 6-day CMB stopped at 1.210% »

Treasury's $25 M…

BHGE

Baker Hughes

$34.63

-0.11 (-0.32%)

12:20
01/19/18
01/19
12:20
01/19/18
12:20
Options
Put buying in Baker Hughes ahead of earnings »

Put buying in Baker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.70

0.55 (3.63%)

12:19
01/19/18
01/19
12:19
01/19/18
12:19
Hot Stocks
Breaking Hot Stocks news story on Momenta 

Momenta trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
01/19/18
01/19
12:17
01/19/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$7.35

0.05 (0.68%)

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Hot Stocks
NuCana to resume trading at 12:30 pm ET »

NuCana is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:15
01/19/18
01/19
12:15
01/19/18
12:15
Hot Stocks
Breaking Hot Stocks news story on Momenta »

Momenta jumps 14%, halted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$14.27

0.18 (1.28%)

12:15
01/19/18
01/19
12:15
01/19/18
12:15
Options
MiMedx put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:14
01/19/18
01/19
12:14
01/19/18
12:14
Periodicals
Breaking Periodicals news story on Momenta »

Momenta weighing options,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:14
01/19/18
01/19
12:14
01/19/18
12:14
Hot Stocks
Breaking Hot Stocks news story on Momenta »

Momenta trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRG

NRG Energy

$26.50

-0.31 (-1.16%)

12:05
01/19/18
01/19
12:05
01/19/18
12:05
Options
NRG Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMNB

American National Bankshares

$39.10

-0.8 (-2.01%)

12:03
01/19/18
01/19
12:03
01/19/18
12:03
Hot Stocks
American National Bankshares announces 300,000 share repurchase program »

American National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBIB

Porter Bancorp

$13.76

0.06 (0.44%)

12:02
01/19/18
01/19
12:02
01/19/18
12:02
Hot Stocks
PBI Bank changes name to Limestone Bank »

In the first weeks of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:01
01/19/18
01/19
12:01
01/19/18
12:01
Hot Stocks
NuCana reports 'promising' clinical data on Acelarin »

NuCana announced interim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

11:55
01/19/18
01/19
11:55
01/19/18
11:55
Hot Stocks
Breaking Hot Stocks news story on NuCana »

NuCana PLC (ADS) trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$46.51

-0.27 (-0.58%)

11:55
01/19/18
01/19
11:55
01/19/18
11:55
Options
Mylan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 08

    Mar

BTC

Bitcoin

, BAC

Bank of America

$31.55

0.07 (0.22%)

11:52
01/19/18
01/19
11:52
01/19/18
11:52
Hot Stocks
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

BAC

Bank of America

$31.55

0.07 (0.22%)

MS

Morgan Stanley

$56.67

0.83 (1.49%)

GS

Goldman Sachs

$252.15

1.18 (0.47%)

V

Visa

$122.10

-1.015 (-0.82%)

AMD

AMD

$12.47

0.29 (2.38%)

NVDA

Nvidia

$224.44

-0.28 (-0.12%)

OSTK

Overstock.com

$71.25

-4.4 (-5.82%)

DPW

DPW Holdings

$2.30

-0.05 (-2.13%)

LBCC

Long Blockchain Corp.

$4.51

0.3 (7.13%)

KODK

Kodak

$10.05

-0.1 (-0.99%)

SSC

Seven Stars Cloud Group

$4.53

-0.1 (-2.16%)

RIOT

Riot Blockchain

$19.80

2.04 (11.49%)

LFIN

Longfin

$44.69

6.09 (15.78%)

TEUM

Pareteum

$2.37

0.01 (0.42%)

SRAX

Social Reality

$4.96

0.17 (3.55%)

GBTC

Bitcoin Investment Trust

$1,857.00

221 (13.51%)

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 15

    Feb

AOS

A.O. Smith

$66.32

0.41 (0.62%)

11:51
01/19/18
01/19
11:51
01/19/18
11:51
Hot Stocks
A.O. Smith announces 29% boost in dividend »

Directors of A. O. Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.